New Zealand markets closed

Shanghai Junshi Biosciences Co., Ltd. (1877.HK)

HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
41.600+0.400 (+0.97%)
At close: 04:08PM HKT
Full screen
Previous close41.200
Open41.450
Bid41.550 x 0
Ask41.600 x 0
Day's range41.250 - 42.200
52-week range21.200 - 68.650
Volume518,800
Avg. volume5,673,009
Market cap65.702B
Beta (5Y monthly)0.48
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings date29 Mar 2019
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est63.54
  • GlobeNewswire

    Junshi Biosciences Announces Acceptance of NDA for VV116 in China

    SHANGHAI, China, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the new drug application (“NDA”) for Deuremidevir Hydrobromide Tablets (project code: JT001/VV116, “VV116”), an oral nucleoside analog anti-SARS-CoV-2 drug, has been accepted by the National Medical Produc

  • GlobeNewswire

    Junshi Biosciences Announces Toripalimab as Perioperative Treatment for Operable NSCLC Patients Met Primary Endpoint in Phase 3 Clinical Study

    SHANGHAI, China, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (“Neotorch”, NCT04158440) of the company’s anti-PD-1 monoclonal antibody, toripalimab, in combination with platinum-con

  • GlobeNewswire

    Junshi Biosciences Announces NEJM Publication of Results of Phase 3 Study of VV116 Versus PAXLOVID for Adults at High Risk for Progression to Severe COVID-19

    SHANGHAI, China, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announces the online publication in New England Journal (NEJM) of the Phase 3 trial (NCT05341609) comparing the efficacy and safety of VV116 (JT001) and nirmatrelvir/ritonavir (“PAXLOVID”) in the treatment of symptomatic